{"id":"https://openalex.org/W2013442295","doi":"https://doi.org/10.3109/10428194.2015.1017821","title":"A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma","display_name":"A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma","publication_year":2015,"publication_date":"2015-02-24","ids":{"openalex":"https://openalex.org/W2013442295","doi":"https://doi.org/10.3109/10428194.2015.1017821","mag":"2013442295","pmid":"https://pubmed.ncbi.nlm.nih.gov/25707288"},"language":"en","primary_location":{"id":"doi:10.3109/10428194.2015.1017821","doi":"https://doi.org/10.3109/10428194.2015.1017821","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428194.2015.1017821","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015361329","display_name":"Nina D. Wagner\u2010Johnston","orcid":"https://orcid.org/0000-0001-6529-9793","observed_orcids":["https://orcid.org/0000-0001-6529-9793"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nina D. Wagner-Johnston","raw_affiliation_strings":["a Washington University School of Medicine , St Louis , MO , USA","Washington University \u2013 St Louis"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Washington University School of Medicine , St Louis , MO , USA","institution_ids":["https://openalex.org/I204465549"]},{"raw_affiliation_string":"Washington University \u2013 St Louis","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089882481","display_name":"Andre Henri Goy","orcid":"https://orcid.org/0000-0001-5125-6522","observed_orcids":["https://orcid.org/0000-0001-5125-6522"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]},{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andr\u00e8 Goy","raw_affiliation_strings":["b The Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA","Rutgers The State University of New Jersey, Newark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b The Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Rutgers The State University of New Jersey, Newark","institution_ids":["https://openalex.org/I102322142"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021262821","display_name":"Maria Alma Rodriguez","orcid":"https://orcid.org/0000-0002-3564-8697","observed_orcids":["https://orcid.org/0000-0002-3564-8697"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria A. Rodriguez","raw_affiliation_strings":["c University of Texas MD Anderson Cancer Center , Houston , TX , USA","University of Texas Health Science Center at Houston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"c University of Texas MD Anderson Cancer Center , Houston , TX , USA","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas Health Science Center at Houston","institution_ids":["https://openalex.org/I919571938"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001768894","display_name":"William Christopher Ehmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268258","display_name":"Penn State Cancer Institute","ror":"https://ror.org/00bzx1854","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4405268258"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Christopher Ehmann","raw_affiliation_strings":["d Penn State Hershey Cancer Institute , Hershey , PA , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"d Penn State Hershey Cancer Institute , Hershey , PA , USA","institution_ids":["https://openalex.org/I4405268258"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012810450","display_name":"Paul A. Hamlin","orcid":"https://orcid.org/0000-0001-9500-1804","observed_orcids":["https://orcid.org/0000-0001-9500-1804"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul A. Hamlin","raw_affiliation_strings":["e Memorial Sloan Kettering Cancer Center , New York , NY , USA","Memorial Sloan- Kettering Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"e Memorial Sloan Kettering Cancer Center , New York , NY , USA","institution_ids":["https://openalex.org/I1334819555"]},{"raw_affiliation_string":"Memorial Sloan- Kettering Cancer Center","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011398209","display_name":"John A. Radford","orcid":"https://orcid.org/0000-0001-7898-2786","observed_orcids":["https://orcid.org/0000-0001-7898-2786"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John Radford","raw_affiliation_strings":["f The University of Manchester and The Christie NHS Foundation Trust , Manchester , UK","University of Manchester\u00a0"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"f The University of Manchester and The Christie NHS Foundation Trust , Manchester , UK","institution_ids":["https://openalex.org/I28407311","https://openalex.org/I4210133995"]},{"raw_affiliation_string":"University of Manchester\u00a0","institution_ids":["https://openalex.org/I28407311"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033073385","display_name":"Catherine Thi\u00e9blemont","orcid":"https://orcid.org/0000-0002-9941-2448","observed_orcids":["https://orcid.org/0000-0002-9941-2448","https://orcid.org/0000-0002-7109-6949"]},"institutions":[{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Catherine Thieblemont","raw_affiliation_strings":["g Hospital Saint Louis , Paris , France","Universit\u00e9 Paris 7"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"g Hospital Saint Louis , Paris , France","institution_ids":["https://openalex.org/I4210144610"]},{"raw_affiliation_string":"Universit\u00e9 Paris 7","institution_ids":["https://openalex.org/I4387154366"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044958787","display_name":"Cheolwon Suh","orcid":"https://orcid.org/0000-0002-9178-4431","observed_orcids":["https://orcid.org/0000-0002-9178-4431"]},"institutions":[{"id":"https://openalex.org/I2801680663","display_name":"Asan Medical Center","ror":"https://ror.org/03s5q0090","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2801680663","https://openalex.org/I4210167194"]},{"id":"https://openalex.org/I40542001","display_name":"University of Ulsan","ror":"https://ror.org/02c2f8975","country_code":"KR","type":"education","lineage":["https://openalex.org/I40542001"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Cheolwon Suh","raw_affiliation_strings":["h Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea","University of ULSAN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"h Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea","institution_ids":["https://openalex.org/I2801680663","https://openalex.org/I40542001"]},{"raw_affiliation_string":"University of ULSAN","institution_ids":["https://openalex.org/I40542001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072154632","display_name":"John William Sweetenham","orcid":"https://orcid.org/0000-0002-9873-2060","observed_orcids":["https://orcid.org/0000-0002-9873-2060","https://orcid.org/0009-0000-4315-0015"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Sweetenham","raw_affiliation_strings":["i Cleveland Clinic , Cleveland , OH , USA","Cleveland Clinic Foundation"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"i Cleveland Clinic , Cleveland , OH , USA","institution_ids":["https://openalex.org/I1316902750"]},{"raw_affiliation_string":"Cleveland Clinic Foundation","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052937521","display_name":"Yifan Huang","orcid":"https://orcid.org/0000-0003-1060-3668","observed_orcids":["https://orcid.org/0000-0003-1060-3668"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yifan Huang","raw_affiliation_strings":["j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062275112","display_name":"Sharon T. Sullivan","orcid":"https://orcid.org/0000-0002-4327-666X","observed_orcids":["https://orcid.org/0000-0002-4327-666X"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon T. Sullivan","raw_affiliation_strings":["j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009581524","display_name":"Erik R. Vandendries","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik R. Vandendries","raw_affiliation_strings":["j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"j Pfizer Oncology , (LaJolla, CA and Cambridge, MA) , USA","institution_ids":["https://openalex.org/I180857899"]},{"raw_affiliation_string":"Pfizer","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086620890","display_name":"Christian Gisselbrecht","orcid":"https://orcid.org/0000-0001-8079-3589","observed_orcids":["https://orcid.org/0000-0001-8079-3589"]},"institutions":[{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christian Gisselbrecht","raw_affiliation_strings":["g Hospital Saint Louis , Paris , France","Universit\u00e9 Paris 7"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"g Hospital Saint Louis , Paris , France","institution_ids":["https://openalex.org/I4210144610"]},{"raw_affiliation_string":"Universit\u00e9 Paris 7","institution_ids":["https://openalex.org/I4387154366"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5015361329"],"corresponding_institution_ids":["https://openalex.org/I204465549"],"apc_list":null,"apc_paid":null,"fwci":5.2001,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.96075015,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":98},"biblio":{"volume":"56","issue":"10","first_page":"2863","last_page":"2869"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":1.0},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9120000004768372},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.9010000228881836},{"id":"https://openalex.org/keywords/high-dose-therapy","display_name":"high-dose therapy","score":0.7940000295639038},{"id":"https://openalex.org/keywords/calicheamicin","display_name":"calicheamicin","score":0.8009999990463257},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.8090000152587891},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9449999928474426},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6620000004768372},{"id":"https://openalex.org/keywords/hepatotoxicity","display_name":"hepatotoxicity","score":0.7260000109672546},{"id":"https://openalex.org/keywords/infection","display_name":"infection","score":0.33899998664855957}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8313454389572144},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.8292392492294312},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.7428616881370544},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7165549993515015},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6139074563980103},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5892019271850586},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.558576226234436},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4815538227558136},{"id":"https://openalex.org/C2779050716","wikidata":"https://www.wikidata.org/wiki/Q4826373","display_name":"Autologous stem-cell transplantation","level":3,"score":0.48154762387275696},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4749446213245392},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.4727029800415039},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4591909945011139},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4575071334838867},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.45280906558036804},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4236876368522644},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.39159631729125977},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3437570333480835},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.3080103397369385},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.24792873859405518},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.14158886671066284},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014182","descriptor_name":"Transplantation, Autologous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016017","descriptor_name":"Odds Ratio","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016403","descriptor_name":"Lymphoma, Large B-Cell, Diffuse","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D016403","descriptor_name":"Lymphoma, Large B-Cell, Diffuse","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D016403","descriptor_name":"Lymphoma, Large B-Cell, Diffuse","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018380","descriptor_name":"Hematopoietic Stem Cell Transplantation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018380","descriptor_name":"Hematopoietic Stem Cell Transplantation","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019172","descriptor_name":"Transplantation Conditioning","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019650","descriptor_name":"Hematopoietic Stem Cell Mobilization","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D036102","descriptor_name":"Peripheral Blood Stem Cell Transplantation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D036102","descriptor_name":"Peripheral Blood Stem Cell Transplantation","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.3109/10428194.2015.1017821","doi":"https://doi.org/10.3109/10428194.2015.1017821","is_oa":false,"landing_page_url":"https://doi.org/10.3109/10428194.2015.1017821","pdf_url":null,"source":{"id":"https://openalex.org/S27064115","display_name":"Leukemia & lymphoma/Leukemia and lymphoma","issn_l":"1026-8022","issn":["1026-8022","1029-2403","1042-8194"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & Lymphoma","raw_type":"journal-article"},{"id":"pmid:25707288","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25707288","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Leukemia & lymphoma","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/4e8c8515-3a3f-45a1-a77b-621b34cf9292","doi":null,"is_oa":false,"landing_page_url":"https://www.scopus.com/pages/publications/84938897233","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Wagner-Johnston, N D, Goy, A, Rodriguez, M A, Ehmann, W C, Hamlin, P A, Radford, J, Thieblemont, C, Suh, C, Sweetenham, J, Huang, Y, Sullivan, S T, Vandendries, E R & Gisselbrecht, C 2015, 'A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma', Leukemia and Lymphoma, vol. 56, no. 10, pp. 2863-2869. https://doi.org/10.3109/10428194.2015.1017821","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1537235822","https://openalex.org/W1954043953","https://openalex.org/W1979300931","https://openalex.org/W2012489109","https://openalex.org/W2029557235","https://openalex.org/W2043873747","https://openalex.org/W2046760482","https://openalex.org/W2073402239","https://openalex.org/W2098484165","https://openalex.org/W2123036289","https://openalex.org/W2126855868","https://openalex.org/W2128272164","https://openalex.org/W2133201432","https://openalex.org/W2137348614","https://openalex.org/W2138874270","https://openalex.org/W2142867377","https://openalex.org/W2143876351","https://openalex.org/W2150587745","https://openalex.org/W2161054245","https://openalex.org/W2191988482","https://openalex.org/W2279123984","https://openalex.org/W2288726496","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W2586606224","https://openalex.org/W2161054245","https://openalex.org/W2337841974","https://openalex.org/W2998768616","https://openalex.org/W2570087103","https://openalex.org/W2596301040","https://openalex.org/W2604901999","https://openalex.org/W2725925241","https://openalex.org/W7108460573","https://openalex.org/W3011699728"],"abstract_inverted_index":{"This":[0],"study":[1],"evaluated":[2],"the":[3],"safety":[4],"and":[5,34,78,108,116,120,130],"efficacy":[6],"of":[7,61,85],"inotuzumab":[8],"ozogamicin":[9],"(INO),":[10],"a":[11,143],"targeted":[12],"humanized":[13],"anti-CD22":[14],"antibody":[15],"conjugated":[16],"to":[17,26],"calicheamicin,":[18],"plus":[19],"rituximab":[20],"(R-INO)":[21],"every":[22],"3":[23],"weeks,":[24],"up":[25],"six":[27],"cycles,":[28],"followed":[29],"by":[30],"high":[31],"dose":[32],"therapy":[33],"autologous":[35],"stem":[36],"cell":[37],"transplant":[38,147],"(HDT-aSCT)":[39],"in":[40,114],"patients":[41,64,94,103,127,149],"with":[42,150],"high-risk":[43],"relapsed/refractory":[44],"diffuse":[45],"large":[46],"B-cell":[47],"lymphoma":[48],"(DLBCL).":[49],"The":[50],"primary":[51],"endpoint":[52],"was":[53,87,104],"overall":[54],"response":[55],"(OR)":[56],"rate":[57,81],"after":[58,82],"three":[59,83],"cycles":[60,84],"R-INO.":[62],"Sixty-three":[63],"were":[65,75,128],"enrolled.":[66],"Common":[67],"grade":[68],"3/4":[69],"adverse":[70],"events":[71],"during":[72],"R-INO":[73,86,136],"treatment":[74],"thrombocytopenia,":[76],"lymphopenia":[77],"neutropenia.":[79],"OR":[80],"28.6%":[88],"(95%":[89],"confidence":[90],"interval:":[91],"17.9-41.4).":[92],"Eighteen":[93],"underwent":[95],"HDT-aSCT;":[96],"2-year":[97,121],"progression-free":[98],"survival":[99],"(PFS)":[100],"for":[101,124,146],"these":[102],"61.1%.":[105],"Serious":[106],"infections":[107],"hepatic":[109],"toxicity":[110],"following":[111],"aSCT":[112],"occurred":[113],"33%":[115],"22%,":[117],"respectively.":[118],"One-":[119],"PFS":[122],"rates":[123],"all":[125],"enrolled":[126],"28.9%":[129],"25.3%,":[131],"respectively":[132],"(median,":[133],"3.0":[134],"months).":[135],"had":[137],"lower":[138],"than":[139],"expected":[140],"activity":[141],"as":[142],"salvage":[144],"regimen":[145],"eligible":[148],"DLBCL.":[151]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}